Persistent elevation of exhaled nitric oxide and modification of corticosteroid therapy in asthma

Respiratory Investigation

Volumn 51, Issue 2, 2013, Pages 84-91

  Hirano, Tsunahiko ^a   Matsunaga, Kazuto ^a   Sugiura, Hisatoshi ^a   Minakata, Yoshiaki ^a   Koarai, Akira ^a   Akamatsu, Keiichiro ^a   Ichikawa, Tomohiro ^a   Furukawa, Kanako ^a   Ichinose, Masakazu ^b  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Airflow limitation; Airway inflammation; Anti inflammatory therapy; Ventilation heterogeneity

Indexed keywords

CORTICOSTEROID; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; NITRIC OXIDE; PREDNISOLONE;

ADULT; AGED; ALVEOLAR NITRIC OXIDE CONCENTRATION; ARTICLE; ASTHMA; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; FRACTIONAL EXHALED NITRIC OXIDE; HUMAN; INTERVENTION STUDY; LUNG CLOSING VOLUME; LUNG FUNCTION; MALE; NITROGEN WASHOUT; PROSPECTIVE STUDY; RESPIRATORY TRACT PARAMETERS; TOTAL LUNG CAPACITY;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADULT; AGED; ASTHMA; BREATH TESTS; FEMALE; HUMANS; MALE; MIDDLE AGED; NITRIC OXIDE; PREDNISOLONE; PROSPECTIVE STUDIES;

EID: 84879263909     PISSN: 22125345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.resinv.2013.01.002     Document Type: Article

References (42)

1. Barnes PJ. Pathophysiology of asthma. Br J Clin Pharmacol 1996, 42:3-10.
2. Bousquet J, Chanez P, Lacoste JY, et al. Eosinophilic inflammation in asthma. N Engl J Med 1990, 323:1033-1039.
3. Berry MA, Shaw DE, Green RH, et al. The use of exhaled nitric oxide concentration to identify eosinophilic airway inflammation: an observational study in adults with asthma. Clin Exp Allergy 2005, 35:1175-1179.
4. Papaioannou AI, Minas M, Tanou K, et al. Exhaled no may predict loss of asthma control: the effect of concomitant allergic rhinitis. Eur Respir J 2009, 34:1006-1007.
5. Michils A, Baldassarre S, Van Muylem A. Exhaled nitric oxide and asthma control: a longitudinal study in unselected patients. Eur Respir J 2008, 31:539-546.
6. Gelb AF, Flynn Taylor C, Shinar CM, et al. Role of spirometry and exhaled nitric oxide to predict exacerbations in treated asthmatics. Chest 2006, 129:1492-1499.
7. van Veen IH, Ten Brinke A, Sterk PJ, et al. Exhaled nitric oxide predicts lung function decline in difficult-to-treat asthma. Eur Respir J 2008, 32:344-349.
8. Dweik RA, Sorkness RL, Wenzel S, et al. Use of exhaled nitric oxide measurement to identify a reactive, at-risk phenotype among patients with asthma. Am J Respir Crit Care Med 2010, 181:1033-1041.
9. Matsunaga K, Yanagisawa S, Hirano T, et al. Associated demographics of persistent exhaled nitric oxide elevation in treated asthmatics. Clin Exp Allergy 2012, 42:775-781.
10. Szefler SJ, Mitchell H, Sorkness CA, et al. Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: a randomised controlled trial. Lancet 2008, 372:1065-1072.
11. Shaw DE, Berry MA, Thomas M, et al. The use of exhaled nitric oxide to guide asthma management: a randomized controlled trial. Am J Respir Crit Care Med 2007, 176:231-237.
12. Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids. New developments. Am J Respir Crit Care Med 1998, 157:S1-53.
13. Nelson HS, Chapman KR, Pyke SD, et al. Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers. J Allergy Clin Immunol 2003, 112:29-36.
14. Partridge MR, van der Molen T, Myrseth SE, et al. Attitudes and actions of asthma patients on regular maintenance therapy: the inspire study. BMC Pulm Med 2006, 6:13.
15. Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The gaining optimal asthma control study. Am J Respir Crit Care Med 2004, 170:836-844.
16. Dweik RA, Boggs PB Erzurum SC, et al. An official ats clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med 2011, 184:602-615.
17. Matsunaga K, Hirano T, Kawayama T, et al. Reference ranges for exhaled nitric oxide fraction in healthy Japanese adult population. Allergol Int 2010, 59:363-367.
18. Smith AD, Cowan JO, Brassett KP, et al. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med 2005, 352:2163-2173.
19. American Thoracic Society, European Respiratory Society. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med 2005;171:912-30.
20. Tsoukias NM, George SC. A two-compartment model of pulmonary nitric oxide exchange dynamics. J Appl Physiol 1998, 85:653-666.
21. Condorelli P, Shin HW, Aledia AS, et al. A simple technique to characterize proximal and peripheral nitric oxide exchange using constant flow exhalations and an axial diffusion model. J Appl Physiol 2007, 102:417-425.
22. Bates CA, Silkoff PE. Exhaled nitric oxide in asthma: from bench to bedside. J Allergy Clin Immunol 2003, 111:256-262.
23. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005, 26:319-338.
24. Cosio M, Ghezzo H, Hogg JC, et al. The relations between structural changes in small airways and pulmonary-function tests. N Engl J Med 1978, 298:1277-1281.
25. Kharitonov SA, Yates D, Robbins RA, et al. Increased nitric oxide in exhaled air of asthmatic patients. Lancet 1994, 343:133-135.
26. Ichinose M, Takahashi T, Sugiura H, et al. Baseline airway hyperresponsiveness and its reversible component: Role of airway inflammation and airway calibre. Eur Respir J 2000, 15:248-253.
27. Smith AD, Cowan JO, Brassett KP, et al. Exhaled nitric oxide: a predictor of steroid response. Am J Respir Crit Care Med 2005, 172:453-459.
28. Little SA, Chalmers GW, MacLeod KJ, et al. Non-invasive markers of airway inflammation as predictors of oral steroid responsiveness in asthma. Thorax 2000, 55:232-234.
29. Perez-de-Llano LA, Carballada F, Castro Anon O, et al. Exhaled nitric oxide predicts control in patients with difficult-to-treat asthma. Eur Respir J 2010, 35:1221-1227.
30. Scichilone N, Battaglia S, Sorino C, et al. Effects of extra-fine inhaled beclomethasone/formoterol on both large and small airways in asthma. Allergy 2010, 65(7):897-902.
31. Hamid Q, Song Y, Kotsimbos TC, et al. Inflammation of small airways in asthma. J Allergy Clin Immunol 1997, 100:44-51.
32. Goldin JG, Tashkin DP, Kleerup EC, et al. Comparative effects of hydrofluoroalkane and chlorofluorocarbon beclomethasone dipropionate inhalation on small airways: assessment with functional helical thin-section computed tomography. J Allergy Clin Immunol 1999, 104:S258-S267.
33. Cohen J, Douma WR, ten Hacken NH, et al. Ciclesonide improves measures of small airway involvement in asthma. Eur Respir J 2008, 31:1213-1220.
34. Tunon-de-Lara JM, Laurent F, Giraud V, et al. Air trapping in mild and moderate asthma: effect of inhaled corticosteroids. J Allergy Clin Immunol 2007, 119:583-590.
35. Lee DK, Haggart K, Currie GP, et al. Effects of hydrofluoroalkane formulations of ciclesonide 400 microg once daily vs fluticasone 250 microg twice daily on methacholine hyper-responsiveness in mild-to-moderate persistent asthma. Br J Clin Pharmacol 2004, 58:26-33.
36. Yamaguchi M, Niimi A, Ueda T, et al. Effect of inhaled corticosteroids on small airways in asthma: investigation using impulse oscillometry. Pulm Pharmacol Ther 2009, 22:326-332.
37. Usmani OS, Biddiscombe MF, Barnes PJ. Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size. Am J Respir Crit Care Med 2005, 172:1497-1504.
38. Michils A, Louis R, Peche R, et al. Exhaled nitric oxide as a marker of asthma control in smoking patients. Eur Respir J 2009, 33:1295-1301.
39. Barnes PJ, Greening AP, Crompton GK. Glucocorticoid resistance in asthma. Am J Respir Crit Care Med 1995, 152:S125-S140.
40. Van Veen IH, Sterk PJ, Schot R, et al. Alveolar nitric oxide versus measures of peripheral airway dysfunction in severe asthma. Eur Respir J 2006, 27:951-956.
41. Barnes PJ, Adcock IM. Glucocorticoid resistance in inflammatory diseases. Lancet 2009, 373:1905-1917.
42. Ten Brinke A, Zwinderman AH, Sterk PJ, et al. "Refractory" eosinophilic airway inflammation in severe asthma: Effect of parenteral corticosteroids. Am J Respir Crit Care Med 2004, 170:601-605.